NGM Biopharmaceuticals, Inc (NGM)

Etorro trading 970x250
NGM Biopharmaceuticals, Inc (NGM) Logo

About NGM Biopharmaceuticals, Inc

NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company’s product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 2b clinical trial for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit growth differentiation factor GDF15 levels on cancer anorexia/cachexia syndrome; NGM621, an antibody in Phase 2 clinical trials for the treatment of geographic atrophy; and NGM707 and NGM438 for the development of treatment of cancer. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California. Address: 333 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

NGM Biopharmaceuticals, Inc News and around…

Latest news about NGM Biopharmaceuticals, Inc (NGM) common stock and company :

Is Good News Enough for You to Buy NGM on the Dip?
06 Oct, 2021 FinancialContent

A drop in the overall market provides an opportunity for investors to pounce.

Raymond James: These 3 Stocks Could Deliver at Least 40% Gains
30 Sep, 2021 Yahoo! Finance

Are the good times for stocks ending? Maybe so, and maybe not; the NASDAQ and the S&P are showing year-to-date gains between 14% and 17%, even after slipping from their all-time highs. The one thing that’s clear is, volatility is higher in the market. But as always in the market, increased risk for some can equal increased opportunities for others. Raymond James stock analysts have been busy picking out the stocks they see as winners, able to swim in the stream of increasingly difficult economic

Analysts Anticipate 22% Upside For The Holdings of IHE
17 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares US.

10 Biggest Price Target Changes For Friday
17 Sep, 2021 FinancialContent

UBS cut FedEx Corporation (NYSE: FDX) price target from $397 to $380. FedEx shares fell 0.2% to $258.00 in pre-market ...

NGM Bio Presents Preliminary Data From NGM120 Solid Tumor Trial
16 Sep, 2021 FinancialContent

NGM Biopharmaceuticals Inc(NASDAQ: NGM)announced preliminary findingsfrom its ongoing Phase 1a/1b dose-escalation ...

NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021
16 Sep, 2021 FinancialContent
Ngm Biopharmaceuticals Insider Trades $775.31 Thousand In Company Stock
15 Sep, 2021 Yahoo! Finance

Jin-Long Chen, Chief Scientific Officer at Ngm Biopharmaceuticals (NASDAQ:NGM), made a large insider sell on September 14, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Chen sold 30,000 shares of Ngm Biopharmaceuticals at a price of $26.08 per share. The total transaction amounted to $775,306. Chen still owns a total of 929,449 of Ngm Biopharmaceuticals worth, $24,286,502. Ngm Biopharmaceuticals shares are tr

72 Biggest Movers From Yesterday
14 Sep, 2021 FinancialContent

Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from ...

Raymond James Upgraded This Biopharma Stock And Sees 44% Upside
13 Sep, 2021 FinancialContent

Raymond James has upgradedNGM Biopharmaceuticals Inc(NASDAQ: NGM) toStrong Buy from Outperformwith a price ...

45 Stocks Moving In Monday's Mid-Day Session
13 Sep, 2021 FinancialContent

Gainers Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news ...

Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2021
13 Sep, 2021 FinancialContent

Upgrades For Bank of America Corp (NYSE:BAC), Odeon Capital upgraded the previous rating of Hold to Buy. For the second ...

10 Biggest Price Target Changes For Monday
13 Sep, 2021 FinancialContent

Keybanc lowered the price target on FedEx Corporation (NYSE: FDX) from $370 to $350. FedEx shares rose 0.6% to $259.00 in pre-market ...

60 Biggest Movers From Friday
13 Sep, 2021 FinancialContent

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported ...

Noteworthy Friday Option Activity: NGM, RFL, TNL
10 Sep, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in NGM Biopharmaceuticals Inc (NGM), where a total of 3,450 contracts have traded so far, representing approximately 345,000 underlying shares. That amounts to about 149.5% of NGM's average daily trading volume over the past month of 230,750 shares..

41 Stocks Moving In Friday's Mid-Day Session
10 Sep, 2021 FinancialContent

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its ...

12 Health Care Stocks Moving In Thursday's After-Market Session
09 Sep, 2021 FinancialContent

Gainers IVERIC bio (NASDAQ:ISEE) shares moved upwards by 31.76% to $11.45 during Thursday's after-market session. Trading volume for ...

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Can Afford To Drive Business Growth
23 Aug, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research
23 Aug, 2021 FinancialContent
Commit To Purchase NGM Biopharmaceuticals At $20, Earn 28.4% Annualized Using Options
19 Aug, 2021 FinancialContent

Investors eyeing a purchase of NGM Biopharmaceuticals Inc (NGM) shares, but cautious about paying the going market price of $21.23/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2022 put at the $20 strike, which has a bid at the time of this writing of $3.70..

NGM Crosses Above Key Moving Average Level
06 Aug, 2021 FinancialContent

In trading on Friday, shares of NGM Biopharmaceuticals Inc (NGM) crossed above their 200 day moving average of $24.49, changing hands as high as $24.54 per share. NGM Biopharmaceuticals Inc shares are currently trading up about 6% on the day..

NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Lags Revenue Estimates
05 Aug, 2021 Yahoo! Finance

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -23.08% and -24.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results
05 Aug, 2021 FinancialContent
Notable Thursday Option Activity: NGM, BE, IIPR
05 Aug, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in NGM Biopharmaceuticals Inc (NGM), where a total of 2,682 contracts have traded so far, representing approximately 268,200 underlying shares. That amounts to about 88.6% of NGM's average daily trading volume over the past month of 302,855 shares..

NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: Should You Buy?
04 Aug, 2021 Yahoo! Finance

NGM Biopharmaceuticals (NGM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Were Hedge Funds Right About NGM Biopharmaceuticals, Inc. (NGM)?
26 Jul, 2021 Yahoo! Finance

In this article we will analyze whether NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead […]

Noteworthy Monday Option Activity: EHTH, NGM, TCRR
26 Jul, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in eHealth Inc (EHTH), where a total volume of 1,915 contracts has been traded thus far today, a contract volume which is representative of approximately 191,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 64.2% of EHTH's average daily trading volume over the past month, of 298,070 shares..

What Makes NGM Biopharmaceuticals (NGM) a New Buy Stock
23 Jul, 2021 Yahoo! Finance

NGM Biopharmaceuticals (NGM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
23 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
22 Jul, 2021 FinancialContent
NGM Crosses Above Average Analyst Target
08 Jul, 2021 FinancialContent

In recent trading, shares of NGM Biopharmaceuticals Inc (NGM) have crossed above the average analyst 12-month target price of $21.80, changing hands for $21.83/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..

NGM Biopharmaceuticals, Inc (NGM) is a NASDAQ Common Stock listed in , ,